Uma candidatura completa num minuto
Currículo e carta de apresentação personalizados, prontos a enviar.
GondolaBio is seeking an experienced Sr. Director of Clinical Pharmacology & Pharmacometrics to shape strategy for oligonucleotide programs. Remote U.S. or on-site/hybrid Palo Alto options available, reporting to the Chief Development Officer.
You will lead first-in-human dose selection, translate nonclinical data to clinical plans, and guide modeling-based decision making across all development stages, building a robust pharmacology and pharmacometrics framework in a fast-moving biotech.
All Jobs > Sr. Director, Clinical Pharmacology & Pharmacometrics
Sr. Director, Clinical Pharmacology & Pharmacometrics
Fully Remote CA
Full-time
Description
Reports to: Chief Development Officer
Location: Remote U.S. or On-site/Hybrid Palo Alto
GondolaBio is a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics for genetic diseases. GondolaBio is an independent sister company to BridgeBio, originally carved out in 2024 after securing $300M in private financing from external investors. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
You are an experienced clinical pharmacology and quantitative pharmacology leader with deep expertise in early clinical development and a strong track record of informing dose selection and development decisions for oligonucleotide therapies. You are comfortable setting strategy at the portfolio and program level while also rolling up your sleeves to execute in a small, fast-moving biotech environment, and you are energized by the opportunity to help build and shape clinical pharmacology and pharmacometrics approaches as the company and pipeline grow.
A successful candidate must have a demonstrated track-record of driving success in translational research, clinical pharmacology, MIDD and regulatory negotiations as an individual contributor and team leader in oligonucleotides. Key areas of emphasis will include but are not limited to clinical dose selection and refinement across all phases of clinical development, FIH and clinical pharmacology study design, development and hands-on application of MIDD using population and statistical framework, as well as mechanistic and translational PK/PD approaches.